Skip to main content
SpringerLink
Log in

Newer Antiepileptic Drugs for Status Epilepticus in Adults: What’s the Evidence?

  • Review Article
  • Published:
CNS Drugs Aims and scope Submit manuscript

Abstract

Status epilepticus (SE) is one of the most frequent neurological emergencies. Despite this, understanding of its pathophysiology and evidence regarding its management is limited. Rapid, effective, and well-tolerated treatment to achieve seizure cessation is advocated to prevent brain damage or potentially lethal outcomes. The last two decades have witnessed an exponential increase in the number of available antiepileptic drugs (AEDs). These compounds, especially lacosamide and levetiracetam, in view of their intravenous formulation, have been increasingly prescribed in SE. These and other newer AEDs present a promising profile in terms of tolerability, with few centrally depressive effects, favorable pharmacokinetic properties, and fewer drug interactions than classical AEDs; conversely, they are more expensive. There is still no clear evidence to suggest a specific beneficial impact of newer AEDs on SE outcome, preventing any strong recommendation regarding their prescription in SE. Further comparative studies are urgently required to clarify their place and optimal use in the armamentarium of SE treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol. 2015;14(6):615–24.

    Article  PubMed  Google Scholar 

  2. Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348–55.

    Article  CAS  PubMed  Google Scholar 

  3. Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia. 1999;40(1):120–2.

    Article  CAS  PubMed  Google Scholar 

  4. Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus—report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515–23.

    Article  PubMed  Google Scholar 

  5. Delaj L, Novy J, Ryvlin P, Marchi NA, Rossetti AO. Refractory and super-refractory status epilepticus in adults: a 9-year cohort study. Acta Neurol Scand. 2017;135(1):92–9.

    Article  CAS  PubMed  Google Scholar 

  6. Beuchat I, Novy J, Rossetti AO. Newer antiepileptic drugs in status epilepticus: prescription trends and outcomes in comparison with traditional agents. CNS Drugs. 2017;31(4):327–34.

    Article  CAS  PubMed  Google Scholar 

  7. Jaques L, Rossetti AO. Newer antiepileptic drugs in the treatment of status epilepticus: impact on prognosis. Epilepsy Behav E&B. 2012;24(1):70–3.

    Article  Google Scholar 

  8. Rossetti AO. Are newer AEDs better than the classic ones in the treatment of status epilepticus? J Clin Neurophysiol. 2016;33(1):18–21.

    Article  PubMed  Google Scholar 

  9. Glauser T, Ben-Menachem E, Bourgeois B, Cnaan A, Guerreiro C, Kalviainen R, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–63.

    Article  CAS  PubMed  Google Scholar 

  10. Brophy GM, Bell R, Claassen J, Alldredge B, Bleck TP, Glauser T, et al. Guidelines for the evaluation and management of status epilepticus. Neurocrit Care. 2012;17(1):3–23.

    Article  PubMed  Google Scholar 

  11. Claassen J, Riviello JJ Jr, Silbergleit R. Emergency neurological life support: status epilepticus. Neurocrit Care. 2015;23(Suppl 2):S136–42.

    Article  PubMed  Google Scholar 

  12. Glauser T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: treatment of convulsive status epilepticus in children and adults: report of the Guideline Committee of the American Epilepsy Society. Epilepsy Curr/Am Epilepsy Soc. 2016;16(1):48–61.

    Article  Google Scholar 

  13. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure J Br Epilepsy Assoc. 2014;23(3):167–74.

    Article  Google Scholar 

  14. Misra UK, Kalita J. A comparison of four antiepileptic drugs in status epilepticus: experience from India. Int J Neurosci. 2016;126(11):1013–9.

    Article  CAS  PubMed  Google Scholar 

  15. Knake S, Gruener J, Hattemer K, Klein KM, Bauer S, Oertel WH, et al. Intravenous levetiracetam in the treatment of benzodiazepine refractory status epilepticus. J Neurol Neurosurg Psychiatry. 2008;79(5):588–9.

    Article  CAS  PubMed  Google Scholar 

  16. Rossetti AO, Bromfield EB. Levetiracetam in the treatment of status epilepticus in adults: a study of 13 episodes. Eur Neurol. 2005;54(1):34–8.

    Article  CAS  PubMed  Google Scholar 

  17. Ruegg S, Naegelin Y, Hardmeier M, Winkler DT, Marsch S, Fuhr P. Intravenous levetiracetam: Treatment experience with the first 50 critically ill patients. Epilepsy Behav E&B. 2008;12(3):477–80.

    Article  Google Scholar 

  18. Ramael S, Daoust A, Otoul C, Toublanc N, Troenaru M, Lu ZS, et al. Levetiracetam intravenous infusion: a randomized, placebo-controlled safety and pharmacokinetic study. Epilepsia. 2006;47(7):1128–35.

    Article  CAS  PubMed  Google Scholar 

  19. Ramael S, De Smedt F, Toublanc N, Otoul C, Boulanger P, Riethuisen JM, et al. Single-dose bioavailability of levetiracetam intravenous infusion relative to oral tablets and multiple-dose pharmacokinetics and tolerability of levetiracetam intravenous infusion compared with placebo in healthy subjects. Clin Ther. 2006;28(5):734–44.

    Article  CAS  PubMed  Google Scholar 

  20. Trinka E. What is the evidence to use new intravenous AEDs in status epilepticus? Epilepsia. 2011;52(Suppl 8):35–8.

    Article  CAS  PubMed  Google Scholar 

  21. Trinka E, Dobesberger J. New treatment options in status epilepticus: a critical review on intravenous levetiracetam. Ther Adv Neurol Disord. 2009;2(2):79–91.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Chakravarthi S, Goyal MK, Modi M, Bhalla A, Singh P. Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci. 2015;22(6):959–63.

    Article  CAS  PubMed  Google Scholar 

  23. Gujjar AR, Nandhagopal R, Jacob PC, Al-Hashim A, Al-Amrani K, Ganguly SS, et al. Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: a prospective, randomized study. Seizure. 2017;49:8–12.

    Article  PubMed  Google Scholar 

  24. Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol. 2012;259(4):645–8.

    Article  CAS  PubMed  Google Scholar 

  25. Mundlamuri RC, Sinha S, Subbakrishna DK, Prathyusha PV, Nagappa M, Bindu PS, et al. Management of generalised convulsive status epilepticus (SE): a prospective randomised controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam—pilot study. Epilepsy Res. 2015;114:52–8.

    Article  CAS  PubMed  Google Scholar 

  26. Brigo F, Bragazzi N, Nardone R, Trinka E. Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. Epilepsy Behav. 2016;64(Pt A):110–5.

  27. Zelano J, Kumlien E. Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review. Seizure. 2012;21(4):233–6.

    Article  PubMed  Google Scholar 

  28. Alvarez V, Januel JM, Burnand B, Rossetti AO. Second-line status epilepticus treatment: comparison of phenytoin, valproate, and levetiracetam. Epilepsia. 2011;52(7):1292–6.

    Article  CAS  PubMed  Google Scholar 

  29. Eue S, Grumbt M, Muller M, Schulze A. Two years of experience in the treatment of status epilepticus with intravenous levetiracetam. Epilepsy Behav. 2009;15(4):467–9.

    Article  CAS  PubMed  Google Scholar 

  30. De Smedt T, Raedt R, Vonck K, Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev. 2007;13(1):57–78.

    Article  PubMed  Google Scholar 

  31. Navarro V, Dagron C, Elie C, Lamhaut L, Demeret S, Urien S, et al. Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2016;15(1):47–55.

    Article  CAS  PubMed  Google Scholar 

  32. Nicolas JM, Hannestad J, Holden D, Kervyn S, Nabulsi N, Tytgat D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fast onset of action. Epilepsia. 2016;57(2):201–9.

    Article  CAS  PubMed  Google Scholar 

  33. Cawello W. Clinical pharmacokinetic and pharmacodynamic profile of lacosamide. Clin Pharmacokinet. 2015;54(9):901–14.

    Article  CAS  PubMed  Google Scholar 

  34. Cawello W, Stockis A, Andreas JO, Dimova S. Advances in epilepsy treatment: lacosamide pharmacokinetic profile. Ann N Y Acad Sci. 2014;1329:18–32.

    Article  CAS  PubMed  Google Scholar 

  35. Chung SS. Lacosamide: new adjunctive treatment option for partial-onset seizures. Expert Opin Pharmacother. 2010;11(9):1595–602.

    Article  CAS  PubMed  Google Scholar 

  36. Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag. 2009;5:757–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Brigo F, Trinka E. Randomized controlled trials in status epilepticus: Size matters. Epilepsia. 2017;58(5):915.

    Article  PubMed  Google Scholar 

  38. Misra UK, Dubey D, Kalita J. A randomized controlled trial of lacosamide versus sodium valproate in status epilepticus. Epilepsia. 2017.

  39. Hofler J, Trinka E. Lacosamide as a new treatment option in status epilepticus. Epilepsia. 2013;54(3):393–404.

    Article  PubMed  Google Scholar 

  40. Strzelczyk A, Zollner JP, Willems LM, Jost J, Paule E, Schubert-Bast S, et al. Lacosamide in status epilepticus: systematic review of current evidence. Epilepsia. 2017;58(6):933–50.

    Article  CAS  PubMed  Google Scholar 

  41. Kellinghaus C, Berning S, Stogbauer F. Intravenous lacosamide or phenytoin for treatment of refractory status epilepticus. Acta Neurol Scand. 2014;129(5):294–9.

    Article  CAS  PubMed  Google Scholar 

  42. Sutter R, Marsch S, Ruegg S. Safety and efficacy of intravenous lacosamide for adjunctive treatment of refractory status epilepticus: a comparative cohort study. CNS Drugs. 2013;27(4):321–9.

    Article  CAS  PubMed  Google Scholar 

  43. Belcastro V, Vidale S, Pierguidi L, Sironi L, Tancredi L, Striano P, et al. Intravenous lacosamide as treatment option in post-stroke non convulsive status epilepticus in the elderly: a proof-of-concept, observational study. Seizure. 2013;22(10):905–7.

    Article  PubMed  Google Scholar 

  44. Miro J, Toledo M, Santamarina E, Ricciardi AC, Villanueva V, Pato A, et al. Efficacy of intravenous lacosamide as an add-on treatment in refractory status epilepticus: a multicentric prospective study. Seizure J Br Epilepsy Assoc. 2013;22(1):77–9.

    Article  CAS  Google Scholar 

  45. Kellinghaus C, Berning S, Immisch I, Larch J, Rosenow F, Rossetti AO, et al. Intravenous lacosamide for treatment of status epilepticus. Acta Neurol Scand. 2011;123(2):137–41.

    Article  CAS  PubMed  Google Scholar 

  46. Santamarina E, Toledo M, Sueiras M, Raspall M, Ailouti N, Lainez E, et al. Usefulness of intravenous lacosamide in status epilepticus. J Neurol. 2013;260(12):3122–8.

    Article  CAS  PubMed  Google Scholar 

  47. Garces M, Villanueva V, Mauri JA, Suller A, Garcia C, Lopez Gonzalez FJ, et al. Factors influencing response to intravenous lacosamide in emergency situations: LACO-IV study. Epilepsy Behav. 2014;36:144–52.

    Article  PubMed  Google Scholar 

  48. Hofler J, Unterberger I, Dobesberger J, Kuchukhidze G, Walser G, Trinka E. Intravenous lacosamide in status epilepticus and seizure clusters. Epilepsia. 2011;52(10):e148–52.

    Article  PubMed  Google Scholar 

  49. Goodwin H, Hinson HE, Shermock KM, Karanjia N, Lewin JJ 3rd. The use of lacosamide in refractory status epilepticus. Neurocrit Care. 2011;14(3):348–53.

    Article  CAS  PubMed  Google Scholar 

  50. Legros B, Depondt C, Levy-Nogueira M, Ligot N, Mavroudakis N, Naeije G, et al. Intravenous lacosamide in refractory seizure clusters and status epilepticus: comparison of 200 and 400 mg loading doses. Neurocrit Care. 2014;20(3):484–8.

    Article  CAS  PubMed  Google Scholar 

  51. Perrenoud M, Andre P, Alvarez V, Stahli C, Decosterd LA, Rossetti AO, et al. Intravenous lacosamide in status epilepticus: correlation between loading dose, serum levels, and clinical response. Epilepsy Res. 2017;135:38–42.

    Article  CAS  PubMed  Google Scholar 

  52. Gillard M, Fuks B, Leclercq K, Matagne A. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol. 2011;664(1–3):36–44.

    Article  CAS  PubMed  Google Scholar 

  53. Niquet J, Suchomelova L, Thompson K, Klitgaard H, Matagne A, Wasterlain C. Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus. Epilepsia. 2017;58(7):1199–207.

    Article  CAS  PubMed  Google Scholar 

  54. Wasterlain CG, Baldwin R, Naylor DE, Thompson KW, Suchomelova L, Niquet J. Rational polytherapy in the treatment of acute seizures and status epilepticus. Epilepsia. 2011;52(Suppl 8):70–1.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Strzelczyk A, Steinig I, Willems LM, Reif PS, Senft C, Voss M, et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals. Epilepsy Behav. 2017;70(Pt A):177–81.

  56. Kalss GRA, Leitinger M, Georg P, Novak H, Neuray C, Kreidenhuber R, Höfler J, Kuchukhidze G, Trinka E. Intravenous Brivaracetam in Status epilepticus—a retrospectie single centre study. Epilepsia. 2018 (in press).

  57. Novy J, Logroscino G, Rossetti AO. Refractory status epilepticus: a prospective observational study. Epilepsia. 2010;51(2):251–6.

    Article  PubMed  Google Scholar 

  58. Garnett WR. Clinical pharmacology of topiramate: a review. Epilepsia. 2000;41(Suppl 1):S61–5.

    Article  CAS  PubMed  Google Scholar 

  59. Bensalem MK, Fakhoury TA. Topiramate and status epilepticus: report of three cases. Epilepsy Behav. 2003;4(6):757–60.

    Article  PubMed  Google Scholar 

  60. Hottinger A, Sutter R, Marsch S, Ruegg S. Topiramate as an adjunctive treatment in patients with refractory status epilepticus: an observational cohort study. CNS Drugs. 2012;26(9):761–72.

    Article  CAS  PubMed  Google Scholar 

  61. Stojanova V, Rossetti AO. Oral topiramate as an add-on treatment for refractory status epilepticus. Acta Neurol Scand. 2012;125(2):e7–11.

    Article  CAS  PubMed  Google Scholar 

  62. Synowiec AS, Yandora KA, Yenugadhati V, Valeriano JP, Schramke CJ, Kelly KM. The efficacy of topiramate in adult refractory status epilepticus: experience of a tertiary care center. Epilepsy Res. 2012;98(2–3):232–7.

    Article  CAS  PubMed  Google Scholar 

  63. Towne AR, Garnett LK, Waterhouse EJ, Morton LD, DeLorenzo RJ. The use of topiramate in refractory status epilepticus. Neurology. 2003;60(2):332–4.

    Article  CAS  PubMed  Google Scholar 

  64. Madzar D, Kuramatsu JB, Gerner ST, Huttner HB. Assessing the value of topiramate in refractory status epilepticus. Seizure. 2016;38:7–10.

    Article  PubMed  Google Scholar 

  65. Novy J, Rossetti AO. Oral pregabalin as an add-on treatment for status epilepticus. Epilepsia. 2010;51(10):2207–10.

    Article  CAS  PubMed  Google Scholar 

  66. Swisher CB, Doreswamy M, Husain AM. Use of pregabalin for nonconvulsive seizures and nonconvulsive status epilepticus. Seizure. 2013;22(2):116–8.

    Article  PubMed  Google Scholar 

  67. Chen JW, Wasterlain CG. Status epilepticus: pathophysiology and management in adults. Lancet Neurol. 2006;5(3):246–56.

    Article  PubMed  Google Scholar 

  68. Naylor DE, Liu H, Wasterlain CG. Trafficking of GABA(A) receptors, loss of inhibition, and a mechanism for pharmacoresistance in status epilepticus. J Neurosci. 2005;25(34):7724–33.

    Article  CAS  PubMed  Google Scholar 

  69. Patsalos PN. The clinical pharmacology profile of the new antiepileptic drug perampanel: a novel noncompetitive AMPA receptor antagonist. Epilepsia. 2015;56(1):12–27.

    Article  CAS  PubMed  Google Scholar 

  70. Redecker J, Wittstock M, Benecke R, Rosche J. Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Epilepsy Behav. 2015;45:176–9.

    Article  PubMed  Google Scholar 

  71. Rohracher A, Hofler J, Kalss G, Leitinger M, Kuchukhidze G, Deak I, et al. Perampanel in patients with refractory and super-refractory status epilepticus in a neurological intensive care unit. Epilepsy Behav. 2015;49:354–8.

    Article  CAS  PubMed  Google Scholar 

  72. Rosche J, Kampf C, Benecke R. Possible effect of perampanel on focal status epilepticus after generalized tonic-clonic status epilepticus. Acta Neurol Belg. 2014;114(3):243–4.

    Article  PubMed  Google Scholar 

  73. Santamarina E, Sueiras M, Lidon RM, Guzman L, Baneras J, Gonzalez M, et al. Use of perampanel in one case of super-refractory hypoxic myoclonic status: Case report. Epilepsy Behav Case Rep. 2015;4:56–9.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Steinhoff BJ, Bacher M, Kurth C, Staack AM, Kornmeier R. Add-on perampanel in Lance-Adams syndrome. Epilepsy Behav Case Rep. 2016;6:28–9.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Thakur KT, Probasco JC, Hocker SE, Roehl K, Henry B, Kossoff EH, et al. Ketogenic diet for adults in super-refractory status epilepticus. Neurology. 2014;82(8):665–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Strzelczyk A, Kortland LM, Knake S, Rosenow F. Stiripentol for the treatment of super-refractory status epilepticus. Acta Neurol Scand. 2015;132(6):435–9.

    Article  CAS  PubMed  Google Scholar 

  77. http://investor.sagerx.com/news-releases/news-release-details/sage-therapeutics-reports-top-line-results-phase-3-status-trial.

  78. Rosenthal ES, Claassen J, Wainwright MS, Husain AM, Vaitkevicius H, Raines S, et al. Brexanolone as adjunctive therapy in super-refractory status epilepticus. Ann Neurol. 2017;82(3):342–52.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Erstad BL, Patanwala AE. Ketamine for analgosedation in critically ill patients. J Crit Care. 2016;35:145–9.

    Article  CAS  PubMed  Google Scholar 

  80. Gaspard N, Foreman B, Judd LM, Brenton JN, Nathan BR, McCoy BM, et al. Intravenous ketamine for the treatment of refractory status epilepticus: a retrospective multicenter study. Epilepsia. 2013;54(8):1498–503.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Litt B, Wityk RJ, Hertz SH, Mullen PD, Weiss H, Ryan DD, et al. Nonconvulsive status epilepticus in the critically ill elderly. Epilepsia. 1998;39(11):1194–202.

    Article  CAS  PubMed  Google Scholar 

  82. Marchi NA, Novy J, Faouzi M, Stahli C, Burnand B, Rossetti AO. Status epilepticus: impact of therapeutic coma on outcome. Crit Care Med. 2015;43(5):1003–9.

    Article  PubMed  Google Scholar 

  83. Sutter R, Marsch S, Fuhr P, Kaplan PW, Ruegg S. Anesthetic drugs in status epilepticus: risk or rescue? A 6-year cohort study. Neurology. 2014;82(8):656–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  84. Logroscino G, Hesdorffer DC, Cascino G, Annegers JF, Hauser WA. Short-term mortality after a first episode of status epilepticus. Epilepsia. 1997;38(12):1344–9.

    Article  CAS  PubMed  Google Scholar 

  85. Rossetti AO, Alvarez V, Januel JM, Burnand B. Treatment deviating from guidelines does not influence status epilepticus prognosis. J Neurol. 2013;260(2):421–8.

    Article  PubMed  Google Scholar 

  86. Towne AR, Pellock JM, Ko D, DeLorenzo RJ. Determinants of mortality in status epilepticus. Epilepsia. 1994;35(1):27–34.

    Article  CAS  PubMed  Google Scholar 

  87. Rossetti AO, Hurwitz S, Logroscino G, Bromfield EB. Prognosis of status epilepticus: role of aetiology, age, and consciousness impairment at presentation. J Neurol Neurosurg Psychiatry. 2006;77(5):611–5.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Bleck T, Cock H, Chamberlain J, Cloyd J, Connor J, Elm J, et al. The established status epilepticus trial 2013. Epilepsia. 2013;54(Suppl 6):89–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Neurosciences, Service de Neurologie, Centre Hospitalier Universitaire Vaudois (CHUV), CHUV-BH07, University of Lausanne, 1011, Lausanne, Switzerland

    Isabelle Beuchat, Jan Novy & Andrea O. Rossetti

Authors
  1. Isabelle Beuchat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jan Novy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea O. Rossetti
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Andrea O. Rossetti.

Ethics declarations

Funding

No sources of funding were used to prepare this manuscript.

Conflict of interest

I. Beuchat, J. Novy, and A.O. Rossetti have no conflicts of interest that are directly related to the content of this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beuchat, I., Novy, J. & Rossetti, A.O. Newer Antiepileptic Drugs for Status Epilepticus in Adults: What’s the Evidence?. CNS Drugs 32, 259–267 (2018). https://doi.org/10.1007/s40263-018-0509-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40263-018-0509-5

Search

Navigation